Impact of T315I Mutation on Chronic Myeloid Leukemia Prognosis
Author Information
Author(s): Kaleem Bushra, Shahab Sadaf, Shamsi Tahir Sultan
Primary Institution: National Institute of Blood Disease and Bone Marrow Transplantation, Karachi, Pakistan
Hypothesis
The study aims to determine the frequency of T315I mutation and its impact on disease prognosis in chronic myeloid leukemia.
Conclusion
The presence of the T315I mutation indicates a higher risk of disease progression and lower survival rates in chronic myeloid leukemia patients.
Supporting Evidence
- 21.6% of patients not responding to treatment had the T315I mutation.
- 58.8% of mutation carriers progressed to the blastic phase of the disease.
- Overall survival for T315I carriers was 81.8% over 96 months.
Takeaway
This study found that a specific mutation in leukemia patients makes it harder for them to respond to treatment, which can lead to worse outcomes.
Methodology
A longitudinal study was conducted on patients with chronic myeloid leukemia to assess the presence of the T315I mutation and its effects on treatment response and survival over 96 months.
Limitations
The study could not monitor cytogenetic and molecular responses at predetermined time points.
Participant Demographics
The median age of mutation carriers was 37.5 years, with a higher prevalence in females (54.5%).
Statistical Information
P-Value
0.02
Confidence Interval
0.072–0.823
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website